6-(4-甲氧苄基氨基)-2-氯嘌呤 | 203436-09-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 6-(4-甲氧苄基氨基)-2-氯嘌呤
• 中文别名: 2-氯-N-(4-甲氧基苄基)-9H-嘌呤-6-胺
• 英文名称: 2-chloro-N-(4-methoxybenzyl)-9H-purin-6-amine
• 英文别名: 2-chloro-N-[(4-methoxyphenyl)methyl]-9H-purin-6-amine；6-(4-methoxybenzylamino)-2-chloropurine；2-chloro-N-[(4-methoxyphenyl)methyl]-7H-purin-6-amine
• CAS: 203436-09-3
• 化学式: C₁₃H₁₂ClN₅O
• 分子量: 289.724
• InChiKey: UHQWIUXGLBJTRI-UHFFFAOYSA-N

物化性质

• 沸点：
  444.4±55.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  75.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-(4-甲氧苄基氨基)-2-氯嘌呤 在 copper(l) iodide 、 三氟乙酸 、 N,N'-二甲基乙二胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-(6-amino-2-((3-phenylpropyl)amino)-9H-purin-9-yl)benzamide
  参考文献：
  名称：

  Targeting different binding sites in the CFTR structures allows to synergistically potentiate channel activity

  摘要：

  Recent evidence shows that combination of correctors and potentiators, such as the drug ivacaftor (VX-770), can significantly restore the functional expression of mutated Cystic Fibrosis Transmembrane conductance Regulator (CFTR), an anion channel which is mutated in cystic fibrosis (CF). The success of these combinatorial therapies highlights the necessity of identifying a broad panel of specific binding mode modulators, occupying several distinct binding sites at structural level. Here, we identified two small molecules, SBC040 and SBC219, which are two efficient cAMP-independent potentiators, acting at low concentration of forskolin with EC50 close to 1 mu M and in a synergic way with the drug VX-770 on several CFTR mutants of classes II and III. Molecular dynamics simulations suggested potential SBC binding sites at the vicinity of ATP-binding sites, distinct from those currently proposed for VX-770, outlining SBC molecules as members of a new family of potentiators. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112116
• 作为产物：
  描述：

  4-甲氧基苄胺 、 2,6-二氯嘌呤 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以76%的产率得到6-(4-甲氧苄基氨基)-2-氯嘌呤
  参考文献：
  名称：

  二氨基嘌呤-啶异二聚体，用于特异性识别含碱基的DNA。对嘌呤环上接头位置的生物活性的影响。

  摘要：

  制备了三个由含有N，N′-取代的胍的接头束缚的a啶-二氨基嘌呤异二聚体。分子的不同之处在于接头在2，6-二氨基嘌呤上的引入位点。比较了新的异二聚体与含无碱基位点的寡核苷酸的相互作用，并在有或没有抗肿瘤烷基化剂BCNU的情况下测量了它们的细胞毒性。

  DOI：

  10.1016/s0960-894x(01)00310-9

文献信息

• [EN] COMPOUNDS FOR IMPROVING MRNA SPLICING<br/>[FR] COMPOSÉS POUR AMÉLIORER L'ÉPISSAGE DE L'ARNM
  申请人：GEN HOSPITAL CORP

  公开号：WO2016115434A1

  公开（公告）日：2016-07-21

  Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.

  本文提供了一些有助于改善细胞内mRNA剪接的化合物。本文提供的示例化合物有助于改善包含至少一个以核苷酸序列CAA结尾的外显子的基因的mRNA剪接。还提供了制备这些化合物的方法以及治疗中枢神经系统疾病的方法。
• Purine inhibitors of cyclin dependent kinase 2
  申请人：CV Therapeutics, Incorporation

  公开号：US05866702A1

  公开（公告）日：1999-02-02

  A 2,6,9-trisubstituted purine composition having the following formula: ##STR1## where X is a amino, oxo, thio, of sulfone moiety, R.sub.1 is a lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heterocycle, hetaryl, substituted hetaryl, aralkyl, heteroaralkyl, heteroalkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, or alkyl cycloheteroalkyl, each having from 1 to 20 carbon atoms; R.sub.2 is hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycle, hetaryl, substituted hetaryl, aralkyl, heteroaralkyl, heteroalkyl, alkyl alkenyl, alkyl alkynyl, alkyl cycloalkyl, or alkyl cycloheteroalkyl; and R.sub.3 is halogen, hydroxyl, thio, alkoxy, alkylthio, lower alkyl, --NR.sub.4 R.sub.5 or a component having the formula: ##STR2## wherein when R.sub.3 is 2-hydroxyethylamino and R.sub.2 is methyl, R.sub.1 -X is not amino, 3-methyl-2-butenylamino, benzylamino, or m-hydroxybenzyl-amino, when R.sub.3 is 2-hydroxyethylamino and R.sub.2 is isopropyl, R.sub.1 -X is not benzylamino, m-hydroxybenzylamino, or 3-methylbutylamino, when R.sub.3 is 2-hydroxyethylamino and R.sub.2 is 2-hydroxyethyl, R.sub.1 -X is not benzylamino and when R.sub.3 is selected from the group consisting of 2-propanol-2-methylamino and 2-dimethylaminoethylamino and R.sub.2 is methyl, then R.sub.1 -X is not benzylamino.

  具有以下公式的2,6,9-三取代嘌呤组成物：##STR1## 其中X是氨基，氧代基，硫代基或磺酰基，R.sub.1是低碳链烷基，取代低碳链烷基，环烷基，取代环烷基，环杂烷基，取代环杂烷基，芳基，取代芳基，杂环，杂芳基，取代杂芳基，芳基烷基，杂芳基烷基，杂基烷基，烷基烯烃基，烷基炔烃基，烷基环烷基或烷基环杂烷基，每个都有1到20个碳原子；R.sub.2是氢，低碳链烷基，取代低碳链烷基，环烷基，取代环烷基，芳基，取代芳基，杂环，杂芳基，取代杂芳基，芳基烷基，杂芳基烷基，杂基烷基，烷基烯烃基，烷基炔烃基，烷基环烷基或烷基环杂烷基；R.sub.3是卤素，羟基，硫代基，烷氧基，烷基硫代基，低碳链烷基，--NR.sub.4 R.sub.5或具有以下公式的组分：##STR2## 当R.sub.3是2-羟乙基氨基且R.sub.2是甲基时，R.sub.1 -X不是氨基，3-甲基-2-丁烯基氨基，苄基氨基或m-羟基苄基氨基；当R.sub.3是2-羟乙基氨基且R.sub.2是异丙基时，R.sub.1 -X不是苄基氨基，m-羟基苄基氨基或3-甲基丁基氨基；当R.sub.3是2-羟乙基氨基且R.sub.2是2-羟乙基时，R.sub.1 -X不是苄基氨基；当R.sub.3选自由2-异丙醇基-2-甲基氨基和2-二甲基氨基乙基氨基且R.sub.2是甲基时，R.sub.1 -X不是苄基氨基。
• COMPOUNDS AND THERAPEUTICAL USE THEREOF
  申请人：Cai Xiong Sui

  公开号：US20070244113A1

  公开（公告）日：2007-10-18

  Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明揭示了4-芳氨基喹唑啉及其类似物，可有效激活半胱氨酸蛋白酶并诱导细胞凋亡。本发明的化合物在治疗各种临床情况中具有用途，其中异常细胞的不受控制的生长和扩散。
• Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha
  申请人：Lum T. Robert

  公开号：US20050080261A1

  公开（公告）日：2005-04-14

  Compounds of the following formula are provided: In the Formula (I), R 1 is —X—R 1 ′; in which R 1 ′ is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl, and X is —NH—. R 2 is lower alkyl optionally substituted with one, two or three groups chosen from hydroxy, lower alkoxy, and halogen. And R 3 is —NR 4 R 5 ; in which R 4 is hydrogen and R 5 is lower alkyl substituted with amino; or (ii) R 4 and R 5 are both lower alkyl optionally substituted with one, two or three groups chosen from hydroxy and amino. It is to be understood that R 1 ′ is not cyclohexylmethyl, phenyl, substituted phenyl, benzyl, phenylethyl, or m-hydroxybenzyl. The compounds inhibit CDK-2 activity and are useful for treating disorders characterized by undesirable cell proliferation.

  提供以下公式的化合物：在公式（I）中，R1为—X—R1′；其中R1′为可选择取代的低烷基、可选择取代的芳基、可选择取代的杂芳基或可选择取代的杂环烷基，X为—NH—。R2为低烷基，可选择取代一个、两个或三个羟基、低烷氧基或卤素基。R3为—NR4R5；其中R4为氢，R5为取代氨基的低烷基；或（ii）R4和R5均为低烷基，可选择取代一个、两个或三个羟基和氨基。应理解R1′不是环己基甲基、苯基、取代苯基、苄基、苯乙基或间羟基苄基。这些化合物能够抑制CDK-2活性，并用于治疗具有不良细胞增殖特征的疾病。
• Purine inhibitors of cyclin dependent kinase 2 & IkappaBalpha
  申请人：CV Therapeutics, Inc.

  公开号：US20020032327A1

  公开（公告）日：2002-03-14

  A 2,6,9-trisubstituted purine composition that is useful for inhibiting cell proliferative disorders and as an antifungal agent.

  一种2,6,9-三取代嘌呤组合物，可用于抑制细胞增殖性疾病和作为抗真菌剂。